EAA publications:

Julian E., Solà-Morales O., Garcia MJ., Brinkhuis F., Pavlovic M., Martín Saborido C., Doeswijk R., Giuliani R., Willemsen A., Goettsch W., Wörmann BJ., Dafni U., Bucher HC., Valderrama BP., Bernardini R., Gianfrate F., Uyl.de Groot CA., Ruof J.: The Role of Medical Societies in the Evolving EU HTA Process: Insights generated at the 2023 Fall Convention of the European Access Academy. Manuscript submitted for publication. (2024)

Brinkhuis F., Julian E., van den Ham H., Gianfrate F., Strammiello V., Berntgen M., Pavlovic M., Mol P., Wasem J., van Dyck W., Cardone A.,

Dierks C., Schiel A., Bernardini R., Solà-Morales O., Ruof J., Goettsch W.: Navigating the path towards successful implementation of the EU HTA Regulation: Key takeaways from the 2023 Spring Convention of the European Access Academy. Manuscript submitted for publication. (2023)

Brinkhuis F., Ruof J., van den Ham H., Gianfrate F., Strammiello V., Berntgen M., Pavlovic M., Mol P., Wasem J., van Dyck W., Cardone A.,

Dierks C., Schiel A., Solà-Morales O., Goettsch W., Julian E.: Evaluating progress towards EU HTA: Insights generated from the European Access Academy’s multi-stakeholder questionnaire. Manuscript submitted for publication. (2023)

Desmet T., Julian, E., Van Dyck W., Simoens S., Huys I., Giuliani R., Toumi M., Dierks C., Dierks J., Cardone A., Houÿez F., Pavlovic M., Berntgen M., Mol P., Schiel A., Goettsch W., Gianfrate F., Capri S., Ryan J., Ducournau P., Solà-Morales O., Ruof J.: An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators. JMAHP 12(1), 21-34, (2024). doi: https://doi.org/10.3390/jmahp12010004

Van Haesendonck L., Ruof J., Desmet T., Van Dyck W., Simoens S., Huys I., Giuliani R., Toumi M., Dierks C., Dierks J., Cardone A., Houÿez F., Pavlovic M., Berntgen M., Mol P., Schiel A., Goettsch W., Gianfrate F., Capri S., Ryan J., Ducournau P., Solà-Morales O., Julian E.: The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire. JMAHP 11, 1, (2023). doi: https://doi.org/10.1080/20016689.2023.2217543

Julian E., Gianfrate F., Sola-Morales O., Mol PGM., Bergmann JF., Salmonson T., Hebborn A., Grande M., Ruof J.: How can a Joint European Health Technology Assessment provide an 'Additional Benefit' over the current Standard of National Assessments?. Health Econ. Rev. 12, 30 (2022). doi: https://doi.org/10.1186/s13561-022-00379-7

Julian E., Pavlovic M., Solá-Morales O., Gianfrate F., Toumi M., Bucher H.C., Dierks C., Greiner W., Mol P., Bergmann JF., Salmonson T., Hebborn A., Grande M., Cardone A., Ruof J.: Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European Access Academy. Health Econ. Rev. 12, 54 (2022). doi: https://doi.org/10.1186/s13561-022-00402-x

EAA Fall Convention October 2023

Haemato- / Oncology - A Pace Maker for EU HTA

Download the Proceedings of the EAA Fall Convention 2023 HERE.

Welcome & Introduction:

Brian Cuffel

(VP & Head of Market Access Oncology at Bayer Pharmaceuticals)

Presentation

Recording:

Andrew Wilson

(Chair, Pharmaceutical Benefits Advisory Committee, Australian Department of Health and Aged Care &  Co-Director, Menzies Centre for Health Policy and Economics, University of Sydney)

Abstract

Recording:

Other relevant publications:

Albin N., Chassagnol F., Bergmann JF.: Early Access to Health Products in France: Major advances of the French ‘Conseil stratégique des industries des santé (CISIS) to be implemented (modalities, regulations, funding). Therapie. 74(1), 103-117 (2019). doi: 10.1016/j.therap.2018.12.002

Allen A., Patrick H., Ruof J., Buchberger B., Varela-Lema L., Kirschner J., Braune S., Roßnagel F., Giménez E., Cuscó XG., Guilhaume C.: Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology-Based Tool to Support and Review Registries. Value in Health (2022 Mar 8) Online ahead of print. doi: 10.1016/j.jval.2021.12.018.

Chassagnol F., Marcelli G., Wagle J., Giuliani G., Traub D., Schaub V., et al.: Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): a first step towards a con-solidated European perspective on comparative effectiveness & safety? Health Policy 124(9), 943–951 (2020). doi: 10.1016/j.healthpol.2020.06.013

Giuliani G, Chassagnol F, Traub D, Gyldmark M, Hebborn A, Ducournau P, Ruof J.: Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view. Health Econ Rev. Sep 21;8(1):24 (2018). doi: 10.1186/s13561-018-0201-y

Gyldmark M., Lampe K., Ruof J., Pöhlmann J., Hebborn A., Kristensen FB.: IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE. Int J Technol Assess Health Care. 34(5):458-463 (2018). doi: 10.1017/S0266462318000594

Jonker CC., de Vries, ST., van den Berg HM., McGettigan P., Hoes AW., Mol PGM.: Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Among Industry and Other Stakeholders. Drug Safety 44: 853 - 861 (2021). doi: 10.1007/s40264-021-01081-z

Julian E., Rasch A., Bussilliat P., Ruof J.: Acceptance of best-available evidence in benefit assessment of medicinal products: An analysis of procedures without availability of a randomized-controlled trial. Gesundh ökon Qual man (2023). doi: 10.1055/a-2142-0794

Sola-Morales O., Volmer T., Mantovani L.: Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. J Mark Access Health Policy 22;7(1) (2019). doi: 10.1080/20016689.2018.1562861